HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John H Krege Selected Research

Pain (Aches)

6/2022Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis.
1/2022The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials.
1/2022Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
8/2021A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN.
9/2020Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
1/2020Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant.
1/2020Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
10/2019Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
10/2019Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
8/2019Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John H Krege Research Topics

Disease

33Osteoporosis
01/2019 - 07/2005
16Migraine Disorders (Migraine)
06/2022 - 01/2019
13Pain (Aches)
06/2022 - 11/2017
6Headache (Headaches)
08/2021 - 07/2019
6Back Pain (Backache)
11/2017 - 07/2005
5Dizziness (Lightheadedness)
06/2022 - 11/2017
4Nausea
01/2021 - 11/2017
4Postmenopausal Osteoporosis
03/2013 - 11/2005
3Breast Neoplasms (Breast Cancer)
03/2013 - 01/2010
2Sleepiness
06/2022 - 07/2019
2Paresthesia (Dysesthesia)
01/2021 - 07/2019
2Fatigue
01/2021 - 07/2019
2Bone Resorption
02/2015 - 11/2005
2Bone Fractures (Bone Fracture)
01/2015 - 05/2006
2Osteoporotic Fractures
02/2006 - 03/2005
1Mental Disorders (Mental Disorder)
09/2020
1Obesity
09/2020
1Hypesthesia (Numbness)
07/2019
1Muscle Weakness
07/2019
1Hip Fractures (Intertrochanteric Fractures)
01/2019
1Vertigo (Positional Vertigo)
01/2019
1Rheumatoid Arthritis
11/2018
1Type 2 Diabetes Mellitus (MODY)
10/2016
1Metabolic Bone Diseases (Osteopenia)
02/2015
1Injection Site Reaction
02/2015
1Acquired Immunodeficiency Syndrome (AIDS)
04/2011
1Ischemia
12/2010
1Venous Thromboembolism
01/2010
1Hypercalciuria
09/2007
1Osteosarcoma (Osteogenic Sarcoma)
02/2007
1Congenital Abnormalities (Deformity)
08/2005

Drug/Important Bio-Agent (IBA)

30Teriparatide (Parathar)FDA Link
01/2019 - 03/2005
17lasmiditanIBA
06/2022 - 01/2019
10Alendronate (Alendronate Sodium)FDA LinkGeneric
12/2018 - 08/2005
9Pharmaceutical PreparationsIBA
01/2021 - 08/2005
7Raloxifene Hydrochloride (Evista)FDA Link
06/2013 - 11/2005
5Pain-FreeIBA
08/2021 - 07/2019
5Biomarkers (Surrogate Marker)IBA
02/2015 - 11/2005
4GlucocorticoidsIBA
11/2018 - 11/2009
3Tryptamines (Triptans)IBA
06/2022 - 01/2020
25-HT1F Serotonin ReceptorIBA
02/2020 - 07/2019
2DenosumabFDA Link
01/2018 - 04/2016
2ProcollagenIBA
11/2017 - 01/2015
2Vitamin DFDA LinkGeneric
06/2012 - 08/2005
2CalciumIBA
09/2007 - 08/2005
1Serotonin (5 Hydroxytryptamine)IBA
02/2020
1rimegepant sulfateIBA
01/2020
1ubrogepantIBA
01/2020
1candesartanIBA
07/2019
1Type A Botulinum Toxins (Botox)FDA Link
07/2019
1Diphosphonates (Bisphosphonates)IBA
11/2018
1Monoclonal AntibodiesIBA
02/2015
1blosozumabIBA
02/2015
1MineralsIBA
01/2015
1hydroxide ionIBA
06/2012
125-hydroxyvitamin DIBA
06/2012
11,25-dihydroxyvitamin DIBA
06/2012
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
12/2010
1AngiotensinsIBA
12/2010
1KininsIBA
12/2010
1OsteocalcinIBA
04/2010
1Procollagen Type IIBA
04/2010
1Bone Density Conservation AgentsIBA
10/2009
1CreatinineIBA
05/2006
1deoxypyridinolineIBA
05/2006
1Alkaline PhosphataseIBA
05/2006
1collagen type I trimeric cross-linked peptideIBA
11/2005

Therapy/Procedure

11Therapeutics
09/2020 - 11/2005
2Duration of Therapy
09/2011 - 11/2005
1Contraindications
06/2022
1Treatment Delay
09/2020
1Fracture Fixation
11/2018
1Activities of Daily Living (ADL)
11/2017
1Hormone Replacement Therapy (Therapy, Hormone Replacement)
02/2006